Bayer gains new Eylea indication in Europe
Following a positive recommendation last month from the European Medicines Agency’s Medicinal Products for Human Use (CHMP; The Pharma Letter July 29), German drug major Bayer (BAYN: DE) says that Eylea (aflibercept solution for injection) has now received final approval from the European Commission for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).
Eylea, a direct competitor to Novartis’ Lucentis (ranibizumab; which is marketed in the USA by Roche), is already approved in the USA for the treatment of neovascular (wet) age-related macular degeneration (AMD) and for macular edema following CRVO. The drug has also been approved in Europe, Japan, Australia and several other countries for use in wet-AMD and in selected countries in South America for macular edema following CRVO.
Backed by encouraging Ph III studies
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze